

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2025

	Shares	Value
COMMON STOCKS [†] - 99.7%		
Biotechnology - 76.0%		
Amgen, Inc.	13,409	\$ 3,743,927
Gilead Sciences, Inc.	33,425	3,705,830
Vertex Pharmaceuticals, Inc.*	7,434	3,309,617
Regeneron Pharmaceuticals, Inc.	5,595	2,937,375
Corteva, Inc.	38,327	2,856,511
Alnylam Pharmaceuticals, Inc.*	8,059	2,627,959
Inmed, Inc.*	17,054	1,716,315
Royalty Pharma plc — Class A	47,112	1,697,445
BeOne Medicines Ltd. ADR*	6,945	1,681,176
Biogen, Inc.*	13,139	1,650,127
Illumina, Inc.*	16,472	1,571,594
United Therapeutics Corp.*	4,886	1,403,992
Exelixis, Inc.*	31,231	1,376,506
Incyte Corp.*	18,961	1,291,244
BioMarin Pharmaceutical, Inc.*	22,683	1,246,885
Moderna, Inc.*	44,631	1,231,369
Blueprint Medicines Corp.*	8,818	1,130,291
Bridgebio Pharma, Inc.*	25,568	1,104,026
CRISPR Therapeutics AG ^{*,1}	21,763	1,058,552
Argenx SE ADR*	1,865	1,028,025
Ionis Pharmaceuticals, Inc.*	25,974	1,026,233
Guardant Health, Inc.*	19,569	1,018,371
Halozyme Therapeutics, Inc.*	18,742	974,959
BioNTech SE ADR ^{*,1}	9,054	963,979
Legend Biotech Corp. ADR*	26,699	947,548
Revolution Medicines, Inc.*	25,526	939,102
TG Therapeutics, Inc.*	24,336	875,853
Roivant Sciences Ltd.*	73,878	832,605
Akero Therapeutics, Inc.*	14,734	786,206
Cytokinetics, Inc.*	23,130	764,215
PTC Therapeutics, Inc.*	15,527	758,339
ADMA Biologics, Inc.*	41,323	752,492
SpringWorks Therapeutics, Inc.*	15,586	732,386
Avidity Biosciences, Inc.*	23,678	672,455
Axsome Therapeutics, Inc.*	6,287	656,300
Ultragenyx Pharmaceutical, Inc.*	18,041	655,971
ACADIA Pharmaceuticals, Inc.*	29,813	643,066
Viking Therapeutics, Inc.*	24,134	639,551
Veracyte, Inc.*	21,678	585,956
Krystal Biotech, Inc.*	4,042	555,613
Nuvalent, Inc. — Class A*	7,173	547,300
Recursion Pharmaceuticals, Inc. — Class A ^{*,1}	107,007	541,455
Arrowhead Pharmaceuticals, Inc.*	34,091	538,638
Crinetics Pharmaceuticals, Inc.*	18,396	529,069
Summit Therapeutics, Inc. ^{*,1}	24,497	521,296
Apellis Pharmaceuticals, Inc.*	29,940	518,261
Ideaya Biosciences, Inc.*	24,125	507,108
Amicus Therapeutics, Inc.*	88,358	506,291
Beam Therapeutics, Inc.*	29,104	495,059
Denali Therapeutics, Inc.*	34,243	479,060
Celldex Therapeutics, Inc.*	22,910	466,219
Arcellx, Inc.*	7,071	465,625
Immunovant, Inc.*	26,041	416,656
Dynavax Technologies Corp.*	41,956	416,204
Intellia Therapeutics, Inc.*	43,449	407,552
Novavax, Inc. ^{*,1}	57,356	361,343
Sarepta Therapeutics, Inc.*	19,771	338,084
Dyne Therapeutics, Inc.*	32,615	310,495
Geron Corp.*	125,006	176,258
Iovance Biotherapeutics, Inc. ^{*,1}	98,290	169,059
Total Biotechnology		62,860,998
Pharmaceuticals - 18.1%		
AbbVie, Inc.	30,252	5,615,376
AstraZeneca plc ADR	24,868	1,737,776
Neurocrine Biosciences, Inc.*	11,012	1,384,098
Viatis, Inc.	141,267	1,261,514
Jazz Pharmaceuticals plc*	10,810	1,147,157
Alkermes plc*	31,754	908,482
Vaxcyte, Inc.*	23,628	768,146
Protagonist Therapeutics, Inc.*	12,961	716,355
Agios Pharmaceuticals, Inc.*	15,687	521,750
Ascendis Pharma A/S ADR*	2,776	479,138
Madrigal Pharmaceuticals, Inc.*	1,536	464,855
Total Pharmaceuticals		15,004,647
Healthcare-Products - 4.5%		
Natera, Inc.*	11,240	1,898,885
Exact Sciences Corp.*	23,484	1,247,940
Twist Bioscience Corp.*	16,438	604,754
Total Healthcare-Products		3,751,579
Healthcare-Services - 1.1%		
Medpace Holdings, Inc.*	2,810	881,946
Total Common Stocks		
(Cost \$48,292,314)		82,499,170
	Face Amount	
REPURCHASE AGREEMENTS ^{††,2} - 0.5%		
J.P. Morgan Securities LLC issued 06/30/25 at 4.37% due 07/01/25	\$ 206,078	206,078
Barclays Capital, Inc. issued 06/30/25 at 4.39% due 07/01/25	88,922	88,922
BofA Securities, Inc.	85,866	85,866

issued 06/30/25 at 4.37% due 07/01/25		
Total Repurchase Agreements		
(Cost \$380,866)		380,866
		Shares
SECURITIES LENDING COLLATERAL^{†,3} - 3.2%		
Money Market Fund^{***}		
First American Government Obligations Fund - Class X, 4.25% ⁴		2,638,906
Total Securities Lending Collateral		2,638,906
(Cost \$2,638,906)		2,638,906
Total Investments - 103.4%		
(Cost \$51,312,086)		\$ 85,518,942
Other Assets & Liabilities, net - (3.4)%		(2,807,921)
Total Net Assets - 100.0%		\$ 82,711,021

- *

Non-income producing security.
- ***

A copy of each underlying unaffiliated fund's financial statements is available at the SEC's website at www.sec.gov.
- †

Value determined based on Level 1 inputs.
- ††

Value determined based on Level 2 inputs.
- 1

All or a portion of this security is on loan at June 30, 2025.
- 2

Repurchase Agreements.
- 3

Securities lending collateral.
- 4

Rate indicated is the 7-day yield as of June 30, 2025.

ADR — American Depositary Receipt
plc — Public Limited Company